News | May 17, 2024
Biocon posts Q4 FY24 PAT at Rs. 135 Cr
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
Revenue from Operations stood at Rs. 2,607 crore, 25% YoY growth. Domestic revenue at Rs. 2,400 crore, 20% YoY growth and export revenue at Rs. 207 crore, 118% YoY growth
Acquisition of biologics manufacturing facility in Bangalore to complete by the end of the third quarter in FY 24
The company's consolidated revenues for the quarter grew 36% to Rs. 3,020 crore on the back of robust performance across all its three businesses
Domestic business was up 41.9% YoY and 27.7% QoQ
Strides Pharma Science reported total income of Rs.3367.29 crores during FY 2020-21
Subscribe To Our Newsletter & Stay Updated
